Cargando…
Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study
BACKGROUND: Sofosbuvir (SOF)- or simeprevir (SIM)-containing regimens are highly effective for treating chronic hepatitis C virus (HCV) infection. These regimens, however, are expensive. Most payers have implemented prior authorization (PA) requirements to ensure that patients who can benefit most h...
Autores principales: | Clements, Karen M., Clark, Robin E., Lavitas, Pavel, Kunte, Parag, Graham, Camilla S., O’Connell, Elizabeth, Lenz, Kimberly, Jeffrey, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397595/ https://www.ncbi.nlm.nih.gov/pubmed/27231798 http://dx.doi.org/10.18553/jmcp.2016.22.6.714 |
Ejemplares similares
-
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population
por: Kouris, George, et al.
Publicado: (2018) -
Overview of Comprehensive Hepatitis C Virus Medication Management in a State Medicaid Program
por: Lavitas, Pavel, et al.
Publicado: (2016) -
Precision of provider licensure data for mapping member accessibility to Medicaid managed care provider networks
por: Bell, Nathaniel, et al.
Publicado: (2018) -
Implementation of an Opioid Management Initiative by a State Medicaid Program
por: Garcia, Maria M., et al.
Publicado: (2014) -
Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications
por: Auty, Samantha G., et al.
Publicado: (2021)